Tsumura & Co.
【Tsumura】2026 Fiscal Year Quarterly Earnings Supplementary Materials | Sales of ¥181 billion (up 6.4% YoY)
According to Tsumura's FY2026 quarterly earnings supplementary materials, sales reached ¥181 billion (up 6.4% YoY), with operating and net income also trending upward. Segments show strong performance domestically and in China.
Key Figures
- Sales: ¥181 billion (up 6.4% YoY)
- Total Consolidated Assets: ¥592,766 million
- Net Income Attributable to Owners of Parent: Unknown
AI要約
Business Performance Overview
According to Tsumura’s FY2026 quarterly earnings supplementary materials, sales reached ¥181 billion (up 6.4% YoY), showing increases both against plans and compared to the previous year. The detailed financial information includes consolidated income statements and balance sheets, indicating steady performance both domestically and internationally. Notably, sales in China have increased significantly, with favorable sales of medical Chinese herbal medicines and healthcare products. The format change from the interim period of FY2025 and the expanded scope of Shanghai Hongqiao Zhongyao Pharmaceutical Co., Ltd. are also reflected.
Impact on Shareholders and Future Outlook
Tsumura aims to continue expanding its domestic and international operations and improving profitability, with expectations of steady performance for FY2026. The stability of consolidated cash flows and asset-liability status suggests a strengthening of the financial base. Continued attention is required on the details of mid-term plans, new product launches, and strategic initiatives.
Tsumura & Co.
Company overview · Stock price · Financial data · All IR
